Next-Generation

Biotech Solutions

With our cutting-edge technology, we’re determined to enhance the safety and efficacy of therapeutic agents for the management of neuropsychiatry and pain conditions.

We’re on a mission to improve patient outcomes and quality of life

By employing cutting-edge delivery technologies with therapeutics that can be used across the mental health treatment spectrum, we aim to provide the safe and effective delivery of psychedelic pharmaceutical medicines.

Our Vision

We believe psychedelics are the next major breakthrough in mental health treatment, but healthcare providers need safer, more controlled ways to improve patient experience and outcomes.

Explore Our Vision

Our Technology

Psycheceutical’s patented NeuroDirect™ non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck.

This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results–while avoiding the GI tract and any unwanted side effects and toxicity.

Explore Our Technology

Our Team

Led by world-class neurosurgeons, our multidisciplinary team incorporates clinical and basic neurosciences to revolutionize our understanding and ability to treat a variety of neurological and neuropsychiatric conditions.

Meet Our Team

Latest News & Updates

PSYCHEDELIC SPOTLIGHT
November 8, 2023

Topical Ketamine: A Game-Changer for PTSD?

EXPRESS PHARMA
November 2023

Creating Non-habit Forming Formulations and Treatment Protocols for Psychedelic Substances is Crucial

PHARMACY TIMES
October 6, 2023

Topical Ketamine: A Promising New Avenue for PTSD Treatment

PRESS RELEASE
August 10, 2023

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect™ Ketamine for PTSD

FREETHINK.COM
July 25, 2023

New Clinical Trial is Testing a Ketamine Skin Cream for PTSD; The Hope is That It’ll Deliver the Benefits of the Drug — Without Causing Hallucinations.

CLINICAL TRIALS ARENA
July 14, 2023

Next-Generation

Biotech Solutions

With our cutting-edge technology, we’re determined to enhance the safety and efficacy of therapeutic agents for the management of neuropsychiatry and pain conditions.

We’re on a mission to improve patient outcomes and quality of life

Our Vision

We believe psychedelics are the next major breakthrough in mental health treatment, but healthcare providers need safer, more controlled ways to improve patient experience and outcomes.

Explore Our Vision

Our Technology

Psycheceutical’s patented NeuroDirect™ non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck.

This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results–while avoiding the GI tract and any unwanted side effects and toxicity.

Explore Our Technology

Our Team

Led by world-class neurosurgeons, our multidisciplinary team incorporates clinical and basic neurosciences to revolutionize our understanding and ability to treat a variety of neurological and neuropsychiatric conditions.

Meet Our Team

Latest News & Updates

Topical Ketamine: A Game-Changer for PTSD?

READ MORE

Creating Non-habit Forming Formulations and Treatment Protocols for Psychedelic Substances is Crucial

READ MORE

Topical Ketamine: A Promising New Avenue for PTSD Treatment

READ MORE

Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect™ Ketamine for PTSD

READ MORE

New Clinical Trial is Testing a Ketamine Skin Cream for PTSD; The Hope is That It’ll Deliver the Benefits of the Drug — Without Causing Hallucinations.

READ MORE

Psycheceutical Starts a Phase I Trial With Topical Ketamine; Prepares for a Phase II Trial With PTSD Patients to Test Neurodirect Topical Ketamine.

READ MORE

As Featured In

Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines.